Jazz Pharmaceuticals PLC JAZZ

Health CarePharmaceuticalsIreland

Last close 215.98 USD on Nov 1, 2026, +27.0% year to date

Quant rating

Quant rating B Rank 53 of 211 in Health Care

Growth C 112 of 211
Valuation A 26 of 211
Quality A 26 of 211
Revisions D 156 of 211
Momentum C 87 of 211

Wall Street consensus Buy (1.77)Average target 294.22 USD +36.2%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 14.0B
Enterprise value: 16.2B
52-week range: 129.00 – 266.15
3-year range: 97.78 – 266.15
Dividend yield: –
Beta (5 years): 0.38
Shares outstanding: 64.9M
Next earnings: Nov 2, 2026

About the company

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Growth and profitability fiscal year ends December 31

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	4,268	4,069	3,834	3,659	3,094	–
Revenue growth	4.9%	6.1%	4.8%	18.3%	30.9%	12.5%
EPS (basic, normalized)	8.38	20.90	18.29	13.20	16.23	–
EPS growth	−59.9%	14.3%	38.6%	−18.7%	–	–
Gross margin	88.2%	89.0%	88.6%	85.2%	85.8%	87.4%
Net margin	−8.4%	13.8%	10.8%	−6.1%	−10.7%	−0.1%
ROE	−8.5%	14.3%	12.2%	−6.4%	−8.6%	0.6%

Balance sheet, last quarter
Cash & short-term investments (mil)	2,200
Current ratio	1.78x
Long-term debt (mil)	3,335
Net debt (mil)	2,152
Total equity (mil)	4,802
Net debt / equity	0.45x
Net debt / EBITDA	2.93x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	4,268	+4.9%	3.8x	735	−58.9%	22.0x	8.38	−59.9%	25.8x
2026	4,719	+10.6%	3.4x	1,438	+95.5%	11.2x	14.83	+77.0%	14.6x
2027	4,982	+5.6%	3.2x	2,364	+64.4%	6.8x	25.90	+74.7%	8.3x
2028	5,432	+9.0%	3.0x	2,343	−0.9%	6.9x	28.42	+9.7%	7.6x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	4,719	+0.1%	+4.5%	+6.1%	14.83	−41.9%	−41.4%	−38.0%
2027	4,982	−0.2%	+3.1%	+4.0%	25.90	−0.8%	+0.2%	+2.8%
2028	5,432	−0.3%	+3.1%	+4.7%	28.42	−1.7%	−2.6%	+7.2%

Earnings surprises EPS beat in 3 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	902	1,024	1,055	1,088	898	1,046	1,126	1,198	1,069	1,208
Sales mean (mil)	954	1,004	1,037	1,060	985	1,047	1,109	1,165	977	1,115
Surprise	−5.4%	+1.9%	+1.8%	+2.7%	−8.9%	−0.1%	+1.6%	+2.8%	+9.5%	+8.3%
EPS reported	2.68	5.30	6.61	6.60	1.68	−8.25	8.13	6.64	6.34	5.71
EPS mean	4.18	4.77	5.50	5.81	4.66	−7.61	5.92	6.52	4.57	6.18
Surprise	−35.9%	+11.1%	+20.2%	+13.5%	−63.9%	−8.5%	+37.3%	+1.9%	+38.9%	−7.5%

Peer comparison Pharmaceuticals

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
JAZZ Jazz Pharmaceuticals PLC	14.0B	2.93x	−8.4%	2.91x	14.6x	8.3x	11.2x	6.8x
ABBV AbbVie Inc.	521.1B	2.63x	6.8%	−87.80x	21.1x	18.3x	18.0x	15.7x
Mean		2.78x	−0.8%	−42.44x	17.8x	13.3x	14.6x	11.3x
Median		2.78x	−0.8%	−42.44x	17.8x	13.3x	14.6x	11.3x

Technical analysis

1M−9.4%
3M−15.9%
1Y+56.4%
3Y+71.3%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Jazz Pharmaceuticals PLC, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	4,268	4,069	3,834	3,659	3,094	2,364
Cost of revenue	503	446	436	541	441	149
Gross profit	3,764	3,623	3,399	3,119	2,653	2,215
Selling, general & administrative expenses	1,809	1,385	1,262	1,209	1,223	854
Research & development	783	884	850	580	506	335
Depreciation/amortization	655	627	608	599	526	260
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	948	10.0	99.8	796	229	392
Other operating expenses	0	0	0	0	0	0
Operating income	−430	717	579	−65.5	170	373
Net interest income (expense)	−198	−246	−281	−307	−283	−97.9
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	0	0	0	0	0	0
Net income before taxes	−628	470	298	−373	−113	275
Provision for taxes	−270	−91.4	−120	−159	216	33.5
Minority interest	–	–	–	–	–	–
Equity in affiliates	−0.7	−1.7	−3.0	−9.9	−0.7	−3.0
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	−358	560	415	−224	−330	239
Extraordinary items	2.1	–	–	–	–	–
Net income	−356	560	415	−224	−330	239
EBIT, normalized	518	727	678	730	399	765
EBITDA, normalized	1,214	1,387	1,317	1,360	952	1,044
Basic EPS, normalized	8.38	20.90	18.29	13.20	16.23	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Jazz Pharmaceuticals PLC, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	2,442	2,993	1,626	881	591	2,133
Receivables	831	717	855	743	563	396
Total inventory	417	480	597	714	1,073	95.4
Prepaid expenses	152	177	185	91.9	131	62.4
Other current assets	324	262	172	176	252	152
Total current assets	4,166	4,629	3,435	2,606	2,611	2,840
Property, plant & equipment	259	227	235	301	343	257
Goodwill	1,829	1,716	1,753	1,693	1,828	958
Intangibles	4,430	4,756	5,418	5,794	7,152	2,195
Long-term investments	–	–	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	976	684	552	441	364	286
Total assets	11,659	12,012	11,393	10,835	12,299	6,536
Liabilities
Accounts payable	122	77.9	103	90.8	100	26.9
Payable/accrued	–	–	–	–	–	–
Accrued expenses	1,030	900	793	803	647	349
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	1,030	31.4	605	31.4	31.4	246
Other current liabilities	60.6	29.0	35.8	8.2	30.1	31.4
Total current liabilities	2,243	1,039	1,537	933	809	654
Long-term debt	4,332	6,082	5,113	5,699	6,025	1,849
Minority interest	–	–	–	–	–	–
Other liabilities	766	798	1,007	1,118	1,499	374
Total liabilities	7,341	7,919	7,656	7,750	8,333	2,876
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	0.1	0.1	0.1	0.1	0.1	0.1
Additional paid-in capital	4,240	3,914	3,700	3,477	3,535	2,634
Retained earnings (accumulated deficit)	647	1,128	879	734	831	1,160
Treasury stock	–	–	–	–	–	–
Other equity	−569	−948	−842	−1,126	−400	−134
Total equity	4,319	4,094	3,737	3,086	3,965	3,660
Total liabilities & shareholders' equity	11,659	12,012	11,393	10,835	12,299	6,536

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Jazz Pharmaceuticals PLC, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	−356	560	415	−224	−330	239
Depreciation, depletion & amortization	696	660	639	629	552	278
Deferred taxes	−445	−208	−260	−292	69.2	−137
Non-cash items	1,442	461	503	1,149	534	605
Changes in working capital	18.9	−76.7	−204	9.9	−48.0	−85.4
Cash from operations	1,356	1,396	1,092	1,272	779	900
Investing activities
Capital expenditures	−210	−48.1	−43.0	−498	−45.5	−379
Other investing cash flows	−1,300	−460	−120	52.0	−5,167	−628
Cash from investing	−1,510	−508	−163	−446	−5,212	−1,008
Financing activities
Financing cash flow items	−75.2	−63.5	−51.0	−45.4	−35.6	−16.9
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	−798	84.0	−254	−484	4,006	545
Cash from financing	−873	20.5	−305	−529	3,971	528
Foreign exchange effects	6.6	−1.7	1.1	−6.2	−3.2	0.4
Net change in cash	−1,021	907	625	290	−466	420
Free cash flow	1,146	1,348	1,049	774	733	520

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 1, 2026 after market close.